News Related to DLBCL

Denileukin Diftitox Shows Promise Before CAR-T Therapy in High-Risk DLBCL

Mar 25, 2026

A phase 1 trial shows denileukin diftitox administered before CAR-T therapy has a favorable safety profile and encouraging efficacy in high-risk DLBCL patients, with an 86% overall response rate and 77% one-year progression-free survival. The treatment demonstrated consistent regulatory T-cell depletion, supporting its immunomodulatory mechanism. Larger controlled studies are needed to confirm these preliminary findings.

Metabolomic Profiling Outperforms Cytokines in Predicting CAR T-Cell Neurotoxicity

Mar 19, 2026

Metabolic pathway scores consistently distinguished patients who developed severe neurologic events after CAR T-cell therapy across six clinical trials, surpassing traditional inflammatory markers in predictive performance.

Citius Oncology Reports LYMPHIR Revenue and Positive Phase 1 CAR-T Combination Data

Mar 04, 2026

Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.